The Transparency Commission: evaluation and reevaluation

Authors
Citation
Jf. Bergmann, The Transparency Commission: evaluation and reevaluation, PRESSE MED, 30(19), 2001, pp. 941-946
Citations number
13
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
PRESSE MEDICALE
ISSN journal
07554982 → ACNP
Volume
30
Issue
19
Year of publication
2001
Pages
941 - 946
Database
ISI
SICI code
0755-4982(20010526)30:19<941:TTCEAR>2.0.ZU;2-4
Abstract
Purpose: The purpose of the French Transparency Commission is to provide sc ientific advice concerning the usefulness, interest and good use of drugs. Drug approval: The work of the Transparency Commission lies at the interfac e between the French or European marketing approval procedures and the heal th and economic prerequisites of the French community. Assessment: The opinion of the French Transparency Commission is used to as sess the medical service provided by a new drug and the improvement of this medical service subsequent to its use. This opinion is taken into consider ation for establishing the reimbursement rate applied by the social securit y organizations and the selling price set by the administration. The expert opinions and recommendations established by the Transparency Commission pa rticipate in implementing good use of drugs.